Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies

Contraception

Volumn 53, Issue 3, 1996, Pages 135-139

  Lidegaard, Øjvind ^a,c   Milsom, Ian ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c NONE   (Denmark)

Author keywords

2nd and 3rd generation OC; Deep venous thrombosis; New epidemiological studies

Indexed keywords

DESOGESTREL; GESTODENE; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE;

CHEMICALLY INDUCED DISORDER; EDITORIAL; FEMALE; HUMAN; RISK FACTOR; THROMBOSIS;

CONTRACEPTIVES, ORAL; DESOGESTREL; FEMALE; HUMANS; NORPREGNENES; RISK FACTORS; THROMBOSIS;

EID: 0030095188     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(96)00035-2     Document Type: Editorial

References (13)

1. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
2. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestins in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
3. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
4. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
5. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-7.
6. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, ruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996;312:88-90.
7. Lidegaard Ø, Milsom I. The pill. The controversy continues. Acta Obstet Gynecol Scand 1996; in press.
8. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: An epidemiologic case-control study. Am J Epidemiol 1969;90:365-80.
9. Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: Effects of lowering oestrogen content. Lancet 1980;i:1097-1101.
10. Böttiger LE, Westerholm B. Oral contraceptives and thromboembolic disease. Acta Med Scand 1991;190: 455-63.
11. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986;292:526.
12. Lidegaard Ø. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ 1993;306:956-63.
13. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study. Stroke 1994; 25:935-42.